IRONWOOD PHARMACEUTICALS, INC. Operating Expenses
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Operating Expenses of $43.96 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-05-04
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for the quarter ending 2023-03-31 was $43.96M, a 10.79% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-09-30 was $40.16M, a 4.12% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-06-30 was $41.58M, a 6.79% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-03-31 was $39.68M, a 8.66% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for fiscal 2011 was $132.01M, a 26.18% increase from fiscal 2010.
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for fiscal 2010 was $104.62M, a 9.97% increase from fiscal 2009.
- IRONWOOD PHARMACEUTICALS, INC. operating expenses for fiscal 2009 was $95.14M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2023-03-31 | $43.96M 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | $40.16M 10-Q · filed 2022-11-03 | $81.74M derived: sum of 2 quarters · filed 2022-11-03 | $121.42M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $41.58M 10-Q · filed 2022-08-04 | $81.26M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $39.68M 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $38.58M 10-Q · filed 2022-11-03 | $77.51M derived: sum of 2 quarters · filed 2022-11-03 | $120.96M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $38.93M 10-Q · filed 2022-08-04 | $82.38M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $43.45M 10-Q · filed 2022-05-05 | |||
| 2012-09-30 | $48.80M 10-Q · filed 2012-11-06 | $104.24M derived: sum of 2 quarters · filed 2012-11-06 | $152.13M 10-Q · filed 2012-11-06 | $191.31M derived: sum of 4 quarters · filed 2012-11-06 |
| 2012-06-30 | $55.44M 10-Q · filed 2012-08-07 | $103.32M 10-Q · filed 2012-08-07 | $142.51M derived: sum of 3 quarters · filed 2012-08-07 | $176.34M derived: sum of 4 quarters · filed 2012-11-06 |
| 2012-03-31 | $47.88M 10-Q · filed 2012-05-10 | $87.07M derived: sum of 2 quarters · filed 2012-05-10 | $120.90M derived: sum of 3 quarters · filed 2012-11-06 | $151.12M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-12-31 | $39.19M 10-K · filed 2012-02-29 | $73.02M derived: sum of 2 quarters · filed 2012-11-06 | $103.23M derived: sum of 3 quarters · filed 2012-11-06 | $132.01M 10-K · filed 2012-02-29 |
| 2011-09-30 | $33.83M 10-Q · filed 2012-11-06 | $64.05M derived: sum of 2 quarters · filed 2012-11-06 | $92.83M 10-Q · filed 2012-11-06 | $122.39M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-06-30 | $30.21M 10-Q · filed 2012-08-07 | $58.99M 10-Q · filed 2012-08-07 | $88.56M derived: sum of 3 quarters · filed 2012-08-07 | $113.78M derived: sum of 4 quarters · filed 2012-08-07 |
| 2011-03-31 | $28.78M 10-Q · filed 2012-05-10 | $58.35M derived: sum of 2 quarters · filed 2012-05-10 | $83.57M derived: sum of 3 quarters · filed 2012-05-10 | $110.07M derived: sum of 4 quarters · filed 2012-05-10 |
| 2010-12-31 | $29.57M 10-K · filed 2012-02-29 | $54.79M derived: sum of 2 quarters · filed 2012-02-29 | $81.29M derived: sum of 3 quarters · filed 2012-02-29 | $104.62M 10-K · filed 2012-02-29 |
| 2010-09-30 | $25.22M 10-K · filed 2012-02-29 | $51.72M derived: sum of 2 quarters · filed 2012-02-29 | $75.06M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $26.50M 10-K · filed 2012-02-29 | $49.83M 10-Q · filed 2011-08-12 | ||
| 2010-03-31 | $23.33M 10-K · filed 2012-02-29 | |||
| 2009-12-31 | $95.14M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |